Ariad Pharmaceuticals Inc fka ARIA

[Whosetosay]

Hasn't so far, even though Orphan Drugs tend to be more profitable for their makers. Ariad management has as a history of mismanaging, i.e. screwing up every turbocharging drug designation they receive for TC's science. Pona's orphan status and its accelerated approval status (Breakthrough Therapy) were totally wasted by Ariad, and Brig's BT early approval track also has been discarded by Ariad, going full term on its trial.

Things won't change substantially for the better until the BoD is cleared out. There is no accountability on the companies key officer's, much less their own incompetence. Just pages and pages of proxy eyewash.